Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of NiCord versus unmanipulated umbilical cord blood transplantation
NL-OMON49347Phase 3Completed
- Sponsor
- Gamida Cell
- Start
- Nov 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of omidubicel in hematopoietic malignancies, leukemia, lymphoma and 2 more (2 arms), sponsored by Gamida Cell. Primary endpoint: Time to neutrophil engraftment. Started Nov 2017; status: completed.
02
Drugs
omidubicel
03
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON49347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49347.